Are some diseases associated with a higher risk of venture capital losses?

Are some diseases associated with a higher risk of venture capital losses? 

Before summer we posted a study correlating venture capital losses in drug development with the magnitude of funding of clinical trials. We have used two approaches to find losses: 1) Companies that Pitchbook registers with a “distressed deal”, 2) Companies with M&A transaction multiples of lower than 1x; focusing on European drug development companies founded after year 2000 and with more than EUR 2M raised.  
 
Below we have studied the correlation between losses and choice of disease area.  

In the left panel we have ranked the indications according to number of losses. 

Some biotech investors, Sunstone included, are reluctant to invest in infectious diseases. The therapy payment models are not attractive and the established industry seems disinclined to buy infectious disease focused companies. The data below confirms that the field is subject to many losses and that some investors have learned the relevance of commercial viability the hard way!  
 
Oncology is the second disease category with a high loss rate, but data from our previous M&A analysis suggests that oncology ranks high in M&A frequency. In the right panel we have normalized losses relative to successes (EUR >50M M&A). Infectious diseases remain risky, while the many losses in oncology seem balanced by a higher likelihood of success – at least over the past 20 years. Cardiovascular diseases also have a high Loss to Success ratio, but numbers are low (11 losses and 1 success) and we hesitate to conclude anything.  
 
We have also analysed the average raise for the three disease areas with the highest number of losses (>20): oncology – EUR 21M per company; infectious diseases – EUR 19M per company; CNS – EUR 16M per company. Surprisingly it appears less costly to fail in CNS. Maybe CNS focused clinical trials are more definitive – whereas oncology trials are more explorative and facilitate a second try – and eventually a more costly failure?  
 
In general, we find that the diseases that seem more exposed to losses match Sunstone’s experiences – and according to the data above, an experience we apparently share with some of our industry colleagues 🙂
 
Let us know what you think!
#sunstonelifescience #lifescience #venturecapital

What do you think?
Let us know in our feed on LinkedIn:

5 latest press releases

Hans T. Scambye joins Sunstone as Venture Partner

Sunstone is delighted to announce that experienced biotech executive and CEO of Galecto Hans T. Schambye will be joining our team as new Venture Partner as of 1st February 2025. With a background as an MD and PhD Hans brings to Sunstone over 25 years of experience...

Neumirna Therapeutics secures euro 20M in Series A financing

Neumirna Therapeutics (‘Neumirna’), an RNA-focused biotech company developing next-generation therapeutics for neurological disorders, is pleased to announce the first closing of its Series A funding round at €20M. The investment was co-led by new investors, Angelini...

Ascelia Pharma Successfully Meets Primary Endpoint with Strong Headline Results in Orviglance Phase 3 Study

Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that liver imaging drug candidate, Orviglance®, significantly improved visualization of focal liver lesions, successfully...

Fund IV company Cardior Pharmaceuticals acquired by Novo Nordisk

Cardior is a leader in the discovery and development of therapies that target RNA as a means to prevent, repair and reverse diseases of the heart. The company’s therapeutic approach targets distinctive non-coding RNAs as a platform for addressing root causes of...

A Sunstone team update

After 17 years as General Partner and co-founder of Sunstone Life Science Ventures and almost 40 years in the life science industry, our colleague Sten Verland will be taking on a part-time role as Venture Partner as of February 1. Sten will continue to manage his...

5 latest articles

Are Series A radically growing?

If you are in the biotech venture capital business, it’s been difficult to avoid conversations about the increasing sizes of Series A financing rounds. We’ve been hearing and reading about a revival of biotech financing, including “Biotech Financing: darkest before...

Saving Lives with Venture Capital

In 2023 we posted our thoughts on how to calculate the potential lifesaving impact of biotech venture capital (https://bit.ly/3z4mL0o) – and we promised to expand on the topic. Unfortunately, or rather fortunately, we got busy making investments in DioGenX, Kynexis...

The VC summer dream – the Fund Returner

The VC summer dream – the Fund ReturnerSunstone has over the past years continuously highlighted observations and learnings from successes in European biotech. The learnings have consolidated, tuned and verified our current investment strategy. Sunstone is today...

Are we making a tangible difference?

We are a Life Science Venture Capital with a passion for investing in drug development, both because it is extremely exciting but also because we contribute to moving new therapies closer to patients with severe, untreated diseases – we matter! – we make a tangible...

Sunstone has supported and funded companies that have been the originator of 20 life-changing products

Since the inception in 2007, Sunstone Life Science Ventures (Sunstone) has co-created, supported and funded life science companies that have been the originator of 20 life-changing products approved for the treatment or diagnosis of patients with cardiovascular,...

Biotech startups in Scandinavia have 460 MEUR at hand – but burn is up – and runway the shortest in 3 years

As the market continues to fluctuate and geopolitical issues continue to impact the economy, it's important to take a closer look at the state of pre-commercial life science companies. At Sunstone, we assisted companies in our portfolio with listings and refinancing,...